Analysis of B‐cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines

Abstract Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID‐19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen‐specific antibody sequence (QASAS) method...

Полное описание

Библиографические подробности

Главные авторы:	Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Kazuhiko Doi, Hironori Sakai, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2024-08-01
Серии:	eJHaem
Предметы:	B‐cell receptor repertoire coronavirus antibody database quantification of antigen‐specific antibody sequence monovalent Omicron XBB.1.5 mRNA vaccination
Online-ссылка:	https://doi.org/10.1002/jha2.932
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!